CN104144916B - 二氢喹唑啉衍生物的苯磺酸盐和甲苯磺酸盐和其作为抗病毒剂的用途 - Google Patents
二氢喹唑啉衍生物的苯磺酸盐和甲苯磺酸盐和其作为抗病毒剂的用途 Download PDFInfo
- Publication number
- CN104144916B CN104144916B CN201380011791.1A CN201380011791A CN104144916B CN 104144916 B CN104144916 B CN 104144916B CN 201380011791 A CN201380011791 A CN 201380011791A CN 104144916 B CN104144916 B CN 104144916B
- Authority
- CN
- China
- Prior art keywords
- base
- salt
- piperazine
- phenyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FYSDQPSXEMTTOO-GWFBKHHKSA-N COc(ccc(C(F)(F)F)c1)c1NC(Nc(c(/C=C\C(OC=N)=O)ccc1)c1F)=O Chemical compound COc(ccc(C(F)(F)F)c1)c1NC(Nc(c(/C=C\C(OC=N)=O)ccc1)c1F)=O FYSDQPSXEMTTOO-GWFBKHHKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012101673A DE102012101673A1 (de) | 2012-02-29 | 2012-02-29 | Salze eines Dihydrochinazolinderivats |
DE102012101673.9 | 2012-02-29 | ||
PCT/EP2013/054109 WO2013127968A1 (de) | 2012-02-29 | 2013-02-28 | Besylat- und tosylatsalze eines dihydrochinazolinderivates und ihre verwendung als antivirale mittel |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104144916A CN104144916A (zh) | 2014-11-12 |
CN104144916B true CN104144916B (zh) | 2016-08-24 |
Family
ID=47884256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380011791.1A Active CN104144916B (zh) | 2012-02-29 | 2013-02-28 | 二氢喹唑啉衍生物的苯磺酸盐和甲苯磺酸盐和其作为抗病毒剂的用途 |
Country Status (19)
Country | Link |
---|---|
US (4) | US9512085B2 (zh) |
EP (1) | EP2820000B1 (zh) |
JP (1) | JP6235493B2 (zh) |
CN (1) | CN104144916B (zh) |
CA (1) | CA2865534C (zh) |
CY (1) | CY1118284T1 (zh) |
DE (1) | DE102012101673A1 (zh) |
DK (1) | DK2820000T3 (zh) |
ES (1) | ES2583360T3 (zh) |
HK (1) | HK1205511A1 (zh) |
HR (1) | HRP20160886T1 (zh) |
HU (1) | HUE027751T2 (zh) |
LT (1) | LT2820000T (zh) |
PL (1) | PL2820000T3 (zh) |
PT (1) | PT2820000T (zh) |
RS (1) | RS54989B1 (zh) |
SI (1) | SI2820000T1 (zh) |
SM (1) | SMT201600343B (zh) |
WO (1) | WO2013127968A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
DE102012101673A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
CA2916143C (en) * | 2013-06-19 | 2019-01-29 | Aicuris Anti-Infective Cures Gmbh | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration |
WO2015088931A1 (en) * | 2013-12-12 | 2015-06-18 | Merck Sharp & Dohme Corp. | Process for making substituted quinazoline compounds |
WO2017091453A1 (en) * | 2015-11-24 | 2017-06-01 | Merck Sharp & Dohme Corp. | Novel processes for making substituted quinazoline compounds using hydrogen bonding catalysts |
US11174270B2 (en) * | 2018-02-08 | 2021-11-16 | Phaeno Therapeutics Co., Ltd. | Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof |
IT202000017617A1 (it) | 2020-07-21 | 2022-01-21 | Olon Spa | Procedimento per la preparazione di un intermedio utilizzato nella sintesi del letermovir |
US20230312485A1 (en) | 2020-08-17 | 2023-10-05 | Lupin Limited | A precipitation process for amorphous letermovir |
CN113880776B (zh) * | 2021-11-16 | 2023-06-16 | 山东诚创蓝海医药科技有限公司 | 一种莱特莫韦中间体的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1784390A (zh) * | 2003-05-02 | 2006-06-07 | 拜耳医药保健股份公司 | 具有抗病毒性能的取代二氢喹唑啉 |
CN101863843A (zh) * | 2005-06-15 | 2010-10-20 | 艾库里斯有限及两合公司 | 制备二氢喹唑啉的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10352499A1 (de) * | 2003-11-11 | 2005-06-09 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline II |
DE102011101446A1 (de) | 2011-05-10 | 2012-11-15 | Aicuris Gmbh & Co. Kg | Herstellung von "Dense Bodies" (DB) |
DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
DE102012101673A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
CA2916143C (en) | 2013-06-19 | 2019-01-29 | Aicuris Anti-Infective Cures Gmbh | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration |
-
2012
- 2012-02-29 DE DE102012101673A patent/DE102012101673A1/de not_active Ceased
-
2013
- 2013-02-28 CA CA2865534A patent/CA2865534C/en active Active
- 2013-02-28 PL PL13709345T patent/PL2820000T3/pl unknown
- 2013-02-28 JP JP2014559231A patent/JP6235493B2/ja active Active
- 2013-02-28 US US14/381,625 patent/US9512085B2/en active Active
- 2013-02-28 LT LTEP13709345.6T patent/LT2820000T/lt unknown
- 2013-02-28 HU HUE13709345A patent/HUE027751T2/en unknown
- 2013-02-28 SI SI201330242A patent/SI2820000T1/sl unknown
- 2013-02-28 WO PCT/EP2013/054109 patent/WO2013127968A1/de active Application Filing
- 2013-02-28 DK DK13709345.6T patent/DK2820000T3/en active
- 2013-02-28 CN CN201380011791.1A patent/CN104144916B/zh active Active
- 2013-02-28 EP EP13709345.6A patent/EP2820000B1/de active Active
- 2013-02-28 PT PT137093456T patent/PT2820000T/pt unknown
- 2013-02-28 RS RS20160574A patent/RS54989B1/sr unknown
- 2013-02-28 ES ES13709345.6T patent/ES2583360T3/es active Active
-
2015
- 2015-06-25 HK HK15106079.4A patent/HK1205511A1/zh unknown
-
2016
- 2016-07-15 HR HRP20160886TT patent/HRP20160886T1/hr unknown
- 2016-07-18 CY CY20161100699T patent/CY1118284T1/el unknown
- 2016-09-30 SM SM201600343T patent/SMT201600343B/it unknown
- 2016-10-31 US US15/338,984 patent/US10287254B2/en not_active Ceased
-
2017
- 2017-07-03 US US15/640,661 patent/US20170362186A1/en not_active Abandoned
-
2021
- 2021-05-14 US US17/320,587 patent/USRE49897E1/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1784390A (zh) * | 2003-05-02 | 2006-06-07 | 拜耳医药保健股份公司 | 具有抗病毒性能的取代二氢喹唑啉 |
CN101863843A (zh) * | 2005-06-15 | 2010-10-20 | 艾库里斯有限及两合公司 | 制备二氢喹唑啉的方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2820000B1 (de) | 2016-04-20 |
USRE49897E1 (en) | 2024-04-02 |
US9512085B2 (en) | 2016-12-06 |
US20170362186A1 (en) | 2017-12-21 |
CA2865534A1 (en) | 2013-09-06 |
SI2820000T1 (sl) | 2016-08-31 |
HRP20160886T1 (hr) | 2016-09-23 |
SMT201600343B (zh) | 2016-11-10 |
LT2820000T (lt) | 2016-11-10 |
CA2865534C (en) | 2019-04-02 |
US10287254B2 (en) | 2019-05-14 |
US20150045371A1 (en) | 2015-02-12 |
HUE027751T2 (en) | 2016-10-28 |
HK1205511A1 (zh) | 2015-12-18 |
PT2820000T (pt) | 2016-07-20 |
JP6235493B2 (ja) | 2017-11-22 |
PL2820000T3 (pl) | 2017-07-31 |
US20170114026A1 (en) | 2017-04-27 |
JP2015508800A (ja) | 2015-03-23 |
RS54989B1 (sr) | 2016-11-30 |
CN104144916A (zh) | 2014-11-12 |
CY1118284T1 (el) | 2017-06-28 |
DE102012101673A1 (de) | 2013-08-29 |
WO2013127968A1 (de) | 2013-09-06 |
ES2583360T3 (es) | 2016-09-20 |
DK2820000T3 (en) | 2016-07-25 |
EP2820000A1 (de) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104144916B (zh) | 二氢喹唑啉衍生物的苯磺酸盐和甲苯磺酸盐和其作为抗病毒剂的用途 | |
CN104144917B (zh) | 二氢喹唑啉衍生物的钠盐和钙盐及其作为抗病毒剂的用途 | |
KR101612642B1 (ko) | 테노포비어 알라펜아미드 헤미푸마레이트 | |
EP3774775B1 (en) | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication | |
CN102190616B (zh) | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 | |
CN110433166A (zh) | 含有抗病毒活性二氢喹唑啉衍生物的药物制剂 | |
EP3873607B1 (en) | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication | |
CN106554347B (zh) | Egfr激酶抑制剂及其制备方法和应用 | |
CN113527293B (zh) | Kras g12c突变蛋白抑制剂及其药物组合物、制备方法和用途 | |
KR20030069796A (ko) | 졸피뎀 헤미타르트레이트 | |
EP3870575B1 (en) | Inhibitors of human immunodeficiency virus replication | |
WO2018010622A1 (zh) | 化合物的晶型及其制备方法、组合物和应用 | |
US9464086B2 (en) | Crystalline forms of N,N-dicyclopropyl-4-(1,5-dimethyl-1 H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-D]pyrrolo[2,3-B]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
JP7076845B2 (ja) | 3,4-ジヒドロチエノ[3,2-d]ピリミジン系化合物の結晶形およびその調製方法 | |
WO2016169908A1 (en) | Uracil derivatives for the treatment of malaria | |
US20150099753A1 (en) | Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine | |
EP1541146B1 (en) | Zolpidem hemitartrate solvate | |
US7977330B2 (en) | Salts and crystal modifications thereof | |
US20150158870A1 (en) | Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine | |
CN102219752A (zh) | 一种1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的新晶型d | |
CN102803221A (zh) | 氘代的ω-二苯基脲及其衍生物以及包含这些化合物的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190116 Address after: Germany Wuppertal Patentee after: AICURIS ANTI-INFECTIVE CURES GmbH Address before: Germany Wuppertal Patentee before: AICURIS GmbH & Co.KG |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Germany Wuppertal Patentee after: AIC246 JSC Address before: Germany Wuppertal Patentee before: AIC246 Lianghe Co. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221027 Address after: Germany Wuppertal Patentee after: AIC246 Lianghe Co. Address before: Germany Wuppertal Patentee before: AICURIS ANTI-INFECTIVE CURES GmbH |